{"id":"NCT00549562","sponsor":"Indiana University School of Medicine","briefTitle":"Study of Paliperidone ER in Adolescents and Young Adults With Autism","officialTitle":"A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2007-10-26","resultsPosted":"2017-05-16","lastUpdate":"2017-05-16"},"enrollment":25,"design":{"allocation":null,"model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Autism"],"interventions":[{"type":"DRUG","name":"Paliperidone ER","otherNames":["Invega"]}],"arms":[{"label":"Paliperidone ER","type":"OTHER"}],"summary":"This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.","primaryOutcome":{"measure":"The Clinical Global Impression-Improvement(CGI-I)","timeFrame":"Week 8","effectByArm":[{"arm":"Paliperidone ER","deltaMin":1.8,"sd":1.3}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22549762"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Excessive Appetite","Weight Gain","Rhinitis/cough","Tiredness","Insomnia"]}}